欧洲S3指南:黏膜类天疱疮的诊断与管理(第二部分)
本指南由欧洲皮肤病与性病学会(EADV)自身免疫性大疱病工作组制定,系统检索MEDLINE和EMBASE至2019年6月的文献,采用S3共识方法。第二部分聚焦黏膜类天疱疮(MMP)的诊断与治疗,推荐直接免疫荧光联合血清学检测,并根据病情轻重给出分层治疗方案。
要点
- 黏膜类天疱疮应以直接免疫荧光检测组织结合IgG/IgA/C3联合血清学检测自身抗体。
- 轻中度MMP一线推荐氨苯砜、甲氨蝶呤或四环素类和/或外用糖皮质激素。
- 重度MMP一线推荐氨苯砜和口服或静脉环磷酰胺和/或口服糖皮质激素。
核心结论
- MMP的诊断应结合直接免疫荧光和血清学自身抗体检测,治疗按病情轻重分层推荐。
- 治疗推荐受限于完全缺乏高质量随机对照试验。
研究设计与样本
- 由EADV自身免疫性大疱病工作组制定的S3共识指南,系统检索MEDLINE和EMBASE至2019年6月,无语言限制。
主要发现
- MMP主要靶抗原为XVII型胶原(BP180),10-25%患者识别层粘连蛋白332。
- 25-30%抗层粘连蛋白332反应的MMP患者与恶性肿瘤相关。
- 多数患者血清自身抗体水平低且比例可变,取决于受累部位。
关键数值与推荐
- 怀疑MMP时推荐直接免疫荧光显微镜检测组织结合IgG、IgA和/或补体C3,联合血清学检测循环自身抗体。
- 循环自身抗体可通过间接免疫荧光、ELISA或免疫印迹检测。
- 轻/中度MMP一线推荐氨苯砜、甲氨蝶呤或四环素类和/或外用糖皮质激素。
- 重度MMP一线推荐氨苯砜和口服或静脉环磷酰胺和/或口服糖皮质激素。
- 针对口腔、眼部、喉部、食管和生殖器MMP等单部位受累给出额外推荐。
临床怎么用
- 对以黏膜病变为主的患者应怀疑MMP,并行直接免疫荧光和血清学检测。
- 根据病情严重程度选择一线治疗方案,轻中度与重度用药不同。
- 单部位MMP(口腔、眼部、喉部、食管、生殖器)需参考额外推荐进行针对性治疗。
局限性
- 治疗推荐受限于完全缺乏高质量随机对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This guideline has been initiated by the task force Autoimmune Blistering Diseases of the European Academy of Dermatology and Venereology, including physicians from all relevant disciplines and patient organizations. It is a S3 consensus-based guideline that systematically reviewed the literature on mucous membrane pemphigoid (MMP) in the MEDLINE and EMBASE databases until June 2019, with no limitations on language. While the first part of this guideline addressed methodology, as well as epidemiology, terminology, aetiology, clinical presentation and outcome measures in MMP, the second part presents the diagnostics and management of MMP. MMP should be suspected in cases with predominant mucosal lesions. Direct immunofluorescence microscopy to detect tissue-bound IgG, IgA and/or complement C3, combined with serological testing for circulating autoantibodies are recommended. In most patients, serum autoantibodies are present only in low levels and in variable proportions, depending on the clinical sites involved. Circulating autoantibodies are determined by indirect IF assays using tissue substrates, or ELISA using different recombinant forms of the target antigens or immunoblotting using different substrates. The major target antigen in MMP is type XVII collagen (BP180), although in 10-25% of patients laminin 332 is recognized. In 25-30% of MMP patients with anti-laminin 332 reactivity, malignancies have been associated. As first-line treatment of mild/moderate MMP, dapsone, methotrexate or tetracyclines and/or topical corticosteroids are recommended. For severe MMP, dapsone and oral or intravenous cyclophosphamide and/or oral corticosteroids are recommended as first-line regimens. Additional recommendations are given, tailored to treatment of single-site MMP such as oral, ocular, laryngeal, oesophageal and genital MMP, as well as the diagnosis of ocular MMP. Treatment recommendations are limited by the complete lack of high-quality randomized controlled trials.
引用
- Schmidt E, Rashid H, Marzano AV, et al. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II. J Eur Acad Dermatol Venereol. 2021. PMID: 34309078. doi:10.1111/jdv.17395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。